ARP Americas LP increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 34.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,247 shares of the company’s stock after buying an additional 1,346 shares during the period. ARP Americas LP’s holdings in Omnicell were worth $371,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. UBS Asset Management Americas Inc. grew its stake in Omnicell by 7.6% in the fourth quarter. UBS Asset Management Americas Inc. now owns 44,361 shares of the company’s stock valued at $3,625,000 after purchasing an additional 3,142 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in Omnicell by 516.3% in the fourth quarter. Cubist Systematic Strategies LLC now owns 3,790 shares of the company’s stock valued at $310,000 after purchasing an additional 3,175 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Omnicell by 67.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,352 shares of the company’s stock worth $274,000 after acquiring an additional 1,348 shares in the last quarter. Man Group plc boosted its holdings in Omnicell by 173.1% in the fourth quarter. Man Group plc now owns 40,371 shares of the company’s stock worth $3,299,000 after acquiring an additional 25,589 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Omnicell by 0.8% in the fourth quarter. Alliancebernstein L.P. now owns 69,653 shares of the company’s stock worth $5,692,000 after acquiring an additional 557 shares in the last quarter. Hedge funds and other institutional investors own 95.79% of the company’s stock.
In other Omnicell news, EVP Scott Peter Seidelmann sold 2,125 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $67.70, for a total value of $143,862.50. Following the completion of the transaction, the executive vice president now directly owns 33,385 shares of the company’s stock, valued at $2,260,164.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Randall A. Lipps sold 3,718 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $75.15, for a total value of $279,407.70. Following the completion of the transaction, the chief executive officer now directly owns 152,116 shares of the company’s stock, valued at $11,431,517.40. The disclosure for this sale can be found here. Insiders own 2.63% of the company’s stock.
Shares of Omnicell stock traded down $1.04 on Friday, reaching $70.29. 286,300 shares of the stock were exchanged, compared to its average volume of 286,808. Omnicell, Inc. has a twelve month low of $54.24 and a twelve month high of $94.85. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 62.20, a PEG ratio of 2.78 and a beta of 1.03. The business has a 50 day moving average price of $67.18 and a two-hundred day moving average price of $72.69.
Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, July 28th. The company reported $0.37 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.14. Omnicell had a return on equity of 9.21% and a net margin of 5.42%. The firm had revenue of $199.62 million during the quarter, compared to the consensus estimate of $182.16 million. During the same quarter in the previous year, the company posted $0.67 earnings per share. The company’s revenue was down 8.2% compared to the same quarter last year. On average, research analysts predict that Omnicell, Inc. will post 1.68 earnings per share for the current fiscal year.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More: What is the significance of the death cross?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.